Inside the Doctor’s Studio: Retina

Released On
April 8, 2020

Expires On
April 8, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Ophthalmology

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Global Education Group and Avlis International, Inc.

 

This activity is supported by educational grants from Allergan and Santen.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The educational design of this activity addresses the needs of Retina Specialists, Retina Fellows, Ophthalmologists (general/comprehensive), Optometrists, Allied health involved in the treatment of patients with neovascular age-related macular degeneration (AMD).

Learning Objectives

After completing this activity, the participant should be better able to:

  • Discuss the impact of the growing number of AMD patients on eye care practice.
  • Describe the unmet need for longer acting agent for the treatment of neovascular AMD.
  • Recognize the burden to patients, caregivers and physicians with current management strategies.
  • Discuss the current disconnect between AMD treatment regimens and outcomes reported in clinical trials to those in the real-world setting, as well as the reasons for the discrepancies.
  • Describe recent data from novel agents that have the potential to require less-frequent dosing, while maintain equivalent visual outcomes and safety profiles to current approved therapies.

Faculty

Arshad Khanani, MD, MA

Arshad Khanani, MD, MA

Dr. Khanani is a Managing Partner/Director of Clinical Trials, Sierra Eye Associates and a Clinical Associate Professor, University of Nevada School of Medicine. He is a fellowship trained vitreo-retinal specialist and is certified by The American Board of Ophthalmology. He graduated magna cum laude in chemistry from Washington University in St. Louis with a Bachelors and Masters degree. While at Washington University, Dr. Khanani was honored with The Howard Hughes Medical Institute Research Award.

Dr. Khanani then returned home to Texas and obtained his medical degree at Texas Tech School of Medicine where he received several prestigious research awards. After finishing his internship at Baylor College of Medicine, Dr. Khanani completed his residency in Ophthalmology at Texas Tech School of Medicine. During his residency, he was unanimously elected as Chief Resident.

Dr. Khanani attended The University of Texas – Southwestern Medical Center in Dallas for a two-year fellowship in the medical and surgical treatment of vitreo-retinal diseases.

Due to his strong interest in clinical research, Dr. Khanani has served as a principal investigator for several clinical trials. His articles have been published in numerous ophthalmology journals. Dr. Khanani has also presented his work at major ophthalmology meetings worldwide and has been invited multiple times as a guest speaker nationally and internationally.

Peter Kaiser, MD

Peter Kaiser, MD

Peter K. Kaiser, MD, is a Staff member of the vitreoretinal faculty of the Cole Eye Institute in the Department of Ophthalmology at Cleveland Clinic's main campus. He was appointed in 1997. Dr. Kaiser is the Founding Director of the Digital Optical Coherence Tomography (OCT) Reading Center at the Cole Eye Institute.

Dr. Kaiser received his medical degree magna cum laude from Harvard Medical School in Boston, Mass. He completed an internship in internal medicine at Massachusetts General Hospital, an ophthalmology residency at the Massachusetts Eye and Ear Infirmary in Boston and a retinal fellowship at Bascom Palmer Eye Institute in Miami, Florida.

Actively involved in retinal clinical research, Dr. Kaiser is study chairman of 4 major, multi-center, international clinical trials and is a principal investigator in multiple other trials. Complementing his research endeavors, Dr. Kaiser serves on numerous scientific advisory boards and addresses his research interests as an invited speaker at national and international conferences.

Dr. Kaiser is a major contributor to medical literature having authored several ophthalmology texts, and more than 200 book chapters, original reports, electronic publications and abstracts. He is an associate editor of the American Journal of Ophthalmology, and serves on the editorial boards of Retina, Retina Today, Retinal Physician and Ocular Surgery News.

Dr. Kaiser has been recognized by the American Academy of Ophthalmology and American Society of Retina Specialists with Achievement and Senior Achievement Awards, and is listed in the "Best Doctors in America" list. He is the team ophthalmologist for the Cleveland Browns (National Football League), Cleveland Cavaliers (National Basketball Association) and the Cleveland Indians (Major League Baseball).

Charles C. Wykoff, M.D., PhD

Charles C. Wykoff, M.D., PhD

Overview
Dr. Charles C. Wykoff is a board-certified Medical and Surgical Retina Specialist and ophthalmologist with Retina Consultants of Houston. Leading a top international research facility for vitreoretinal diseases, Dr. Wykoff serves as Director of Research at RCH and the Greater Houston Retina Research Foundation (GHRRF). In addition, he serves as the elected Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital. Dr. Wykoff was awarded the American Academy of Ophthalmology Achievement Award in 2015, the American Society of Retina Specialists Honor Award in 2016 and Senior Honor Award in 2018, and was appointed to the OSN Retina 150 in 2016 as an Innovator in Medical and Surgical Retina.

Skills and Specialties
Skills and Specialties Dr. Wykoff has extensive expertise in clinical trial design and coordination, as well as translational research, publishing over 100 peer-reviewed scientific articles. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgical topics such as retinal tears and retinal detachments, as well as macular surgery for macular holes and macular puckers. He is highly trained and skilled to perform a variety of surgical procedures, and also works with patients to hold off surgery as long as possible with conservative, nonsurgical treatment when possible.

Personal
Dr. Wykoff is an elected member of the Retina Society and the Macula Society, and performs editorial responsibilities including serving as a founding member of the Ophthalmology Retina Editorial Board. Dr. Wykoff holds leadership positions in many scholarly societies including actively serving as the Academic Program Director for the Vit-Buckle Society.

Jeffrey Heier, MD

Jeffrey Heier, MD

Dr. Heier is the Co-President and Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston (OCB), one of the largest and most prestigious multi-specialty ophthalmology practices in the United States.

Dr. Heier received his medical degree from Boston University, then did a transitional internship and ophthalmology residency at Fitzsimons Army Medical Center. Between his internship and residency, Dr. Heier served as a physician in a Combat Support Hospital in the Persian Gulf War, where he was awarded a Bronze Star. Dr. Heier then completed a vitreoretinal fellowship at Ophthalmic Consultants of Boston/Tufts University School of Medicine.

Dr. Heier is on the Executive Board of the Retina Society, on the Executive Committee of the American Society of Retinal Specialists, and a member of the Macula Society. He is past President of the New England Ophthalmological Society, past Secretary of Online Education for the American Academy of Ophthalmology and past President of the Center for Eye Research and Education Foundation in Boston, MA.

From the American Academy of Ophthalmology, Dr. Heier received the Senior Achievement Award in 2010, the Secretariat Award in 2007, and the Honor Award in 2003. He is also the recipient of the Honor Award and Senior Honor Award from the American Society of Retina Specialists.

Dr. Heier is one of the leading retinal clinical researchers in the country for new treatments in exudative and non-exudative macular degeneration, diabetic macular edema, venous occlusive disease, vitreoretinal surgical techniques and instrumentation, and diagnostic imaging of the retina. He serves on the Scientific Advisory Board or as Clinical Design Consultant to over thirty biotechnical or pharmaceutical companies. Dr. Heier is the lead investigator on numerous clinical trials, ranging from phase I safety and proof of concept trials to phase IV post-marketing studies.

Dr. Heier lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases. He has authored or co-authored over 100 works in peer-reviewed journals, as well as served as a reviewer for the New England Journal of Medicine, Lancet, Ophthalmology, Archives of Ophthalmology, American Journal of Ophthalmology, Retina, and numerous other journals.

Dr. Heier enjoys spending time with his wife of over 30 years and his two beautiful daughters, one a staff member at the American Ballet Theatre in NYC and the other a dancer in the Pennsylvania Ballet.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Avlis International, Inc. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Arshad Khanani

  • Consultant/Independent Contractor: Adverum, Allergan, Alcon, Allegro, Bausch and Lomb, Eyepoint, Gemini, Genentech, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Polyphotonix, Regenxbio, Recens Medical, Roche
  • Grant/Research Support: Adverum, Allergan, Alcon, Allegro, Bausch and Lomb, Eyepoint, Gemini, Genentech, Gyroscope, Iveric Bio, Kodiak, Novartis, Opthea, Oxurion, Polyphotonix, Regenxbio, Recens Medical, Roche
  • Honoraria: Adverum, Allergan, Alcon, Allegro, Bausch and Lomb, Eyepoint, Gemini, Genentech, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Polyphotonix, Regenxbio, Recens Medical, Roche
  • Speaker's Bureau: Allergan, Genentech, Novartis
  • Advisory Board: Adverum, Allergan, Gemini, Genentech, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Polyphotonix, Regenxbio, Recens Medical, Roche

Charles Wykoff

  • Consultant/Independent Contractor: Acuela, Adverum, Aerpio, Alimera Sciences, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Santen, Takeda, Xbrane Biopharma
  • Grant/Research Support: Adverum, Aerie Pharmaceuticals, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, IONIS Pharmaceuticals, Iveric Bio, Kodiak, Neurotech, Novartis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Samsung, Santen, Xbrane Biopharma
  • Honoraria: Acuela, Adverum, Aerpio, Alimera Sciences, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Santen, Takeda, Xbrane Biopharma
  • Speaker's Bureau: Regeneron
  • Advisory Board: Acuela, Adverum, Aerpio, Alimera Sciences, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside Biomedical, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Santen, Takeda, Xbrane Biopharma

Peter Kaiser

  • Consultant/Independent Contractor: Aerie, Aerpio, Alcon, Allegro, Allergan, Alzheon, Annexon Biosciences, AsclepiX, Bayer, Bausch and Lomb, Biogen Idec, Boerenger Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, Eyevensys, Formycon/BioEq GmbH, Galecto Biotech, Galimedix, Glaukos, Innovent, iRenix, jCyte, Kala Pharmaceuticals, Kanghong, Kodiak, NGM Biopharmaceuticals, Inc., Novartis , Ocugenix, Oculis, Omeros, Opthea, Oxurion (Thrombogenics), Regeneron, RegenxBio, Retinal Sciences, Roivant, Sandiz, Santen, SciFluor, Spark, Stealth Biotherapeutics, Takeda, Thea, Verena (Digisight)
  • Grant/Research Support: Stealth
  • Stock Shareholder: Allegro

Jeffrey Heier

  • Consultant/Independent Contractor: 4D Molecular Therapeutics, Adverum, Aerie, Aerpio, Aldeyra, Alkahest, Allegro, Allergan, Alzheon, Apellis, Array, Asclepix, Eloxx, Galimedix, Genentech/Roche, Generation Bio, Gyroscope, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong, Kodiak, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Oculis, Omeicos, Orbit, Regeneron, Regenxbio, Retrotope, Scifluor, Shire, Santen, Stealth, Voyant
  • Grant/Research Support: Aerpio, Apellis, Clearside, Genentech/Roche, Genzyme, Gyroscope, Hemera, Janssen R&D, jCyte, KalVista, Kanghong, Novartis, Ophthotech, Regeneron, Regenxbio, Stealth, TLC
  • Stock Shareholder: Adverum, Aldeyra, Allegro, Aviceda, jCyte, Digital Surgical Systems, Ocular Therapeutix

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Lindsay Borvansky

  • Nothing to disclose.

Andrea Funk

  • Nothing to disclose.

Liddy Knight

  • Nothing to disclose.

Ashley Cann

  • Nothing to disclose.

Sue Silva

  • Nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Avlis International, Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

This activity was released on 4/8/2020 and is valid for one year. Requests for credit must be made no later than 4/8/2021.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.